An observational study in Sepsis, sponsored by Kang Yan. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-06.
Sponsored by Kang Yan · Observational
The purpose of the study is to evaluate whether variability of CPP (cerebral perfusion pressure) is related to sepsis-associated encephalopathy and outcomes of patients with sepsis.
Encephalopathy is a common complication of sepsis, impaired cerebrovascular autoregulation (AR) in patients with sepsis is considered related to Sepsis-associated encephalopathy (SAE). As AR is important in stabilizing the cerebral perfusion pressure, whether greater variability of CPP is related to SAE and mortality or not remains unclear. We conduct this study to evaluate the relationship between them.
1,899 studies on the registry are indexed under Sepsis; 462 are open to participants now.
This study's enrollment of 110 is below the median of 160 across 931 observational studies indexed under Sepsis.
Browse Sepsis studies →Kang Yan is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
all patients admit to the general ICU of an academic teaching hospital
Exclusion Criteria:
patient who develop encephalopathy in the progress of sepsis
Other: no interventions
patient who do not develop encephalopathy in the progress of sepsis
Other: no interventions
relationship between cerebral perfusion pressure variability and sepsis-associated encephalopathy
To estimate CPP noninvasively, we will monitor the middle cerebral artery flow velocity of patients with sepsis using transcranial Doppler ultrasound in the first 72h of their enrollment. Diagnosis of a SAE was performed using the confusion assessment method for ICU(CAM-ICU).
Time frame: cerebral perfusion pressure is assessed up to 72 hours
Duration of mechanical ventilation
Time frame: All the participants will be followed up until discharge or death, assessed up to 24 months
Time of ICU stay
Time frame: All the participants will be followed up until discharge or death, assessed up to 24 months
Time of hospital stay
Time frame: All the participants will be followed up until discharge or death, assessed up to 24 months
90-day mortality rate
Time frame: All the participants will be followed up until 90 days after their enrollment or death
1-year mortality rate
Time frame: All the participants will be followed up until 1 year after their enrollment or death
2-year mortality rate
Time frame: All the participants will be followed up until 2 years after their enrollment or death
1-year quality of life of survivors
EQ-5D will be used to evaluate quality of life of survivors
Time frame: All the participants will be followed up until 1 year after their enrollment or death
2-year quality of life of survivors
EQ-5D will be used to evaluate quality of life of survivors
Time frame: All the participants will be followed up until 2 year after their enrollment or death
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kang Yan